Moolec Science (MLECW) Non-Current Deferred Tax Liability (2023 - 2026)
Moolec Science (MLECW) posted Non-Current Deferred Tax Liability of $14.3 million for Q1 2026, little changed sequentially from $14.3 million in Q4 2025.
Moolec Science (MLECW) Non-Current Deferred Tax Liability (2023 - 2026) Analysis & Trends
Moolec Science has reported Non-Current Deferred Tax Liability for 4 years, with the latest figure at $14.3 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.3 million (changed N/A YoY) and the FY2025 annual result came in at $14.4 million, down 58.18% from the prior year.
- Non-Current Deferred Tax Liability was little changed at $14.3 million in Q1 2026 per MLECW's latest filing, from $14.3 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $34.5 million in Q2 2024 and troughed at $40491.0 in Q3 2024.
- A 4-year average of $7.5 million and a median of $1.1 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability slumped 95.2% in 2024, then surged 4424.96% in 2025.
- Over 4 years, Non-Current Deferred Tax Liability stood at $323391.0 in 2023, then retreated by 2.27% to $316039.0 in 2024, then soared by 4424.96% to $14.3 million in 2025, then declined by 0.0% to $14.3 million in 2026.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $14.3 million, $14.3 million, and $14.4 million for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.30 Mn |
| Mar 31, 2026 | 14.30 Mn |
| Dec 31, 2025 | 14.30 Mn |
| Dec 31, 2025 | 14.30 Mn |
| Jun 30, 2025 | 14.43 Mn |
| Jun 30, 2025 | 14.43 Mn |
| Dec 31, 2024 | 316,039.00 |
| Dec 31, 2024 | 316,039.00 |
| Sep 30, 2024 | 40,491.00 |
| Sep 30, 2024 | 40,491.00 |
| Jun 30, 2024 | 34.50 Mn |
| Jun 30, 2024 | 34.50 Mn |
| Mar 31, 2024 | 588,965.00 |
| Mar 31, 2024 | 588,965.00 |
| Dec 31, 2023 | 323,391.00 |
| Dec 31, 2023 | 323,391.00 |
| Sep 30, 2023 | 843,032.00 |
| Sep 30, 2023 | 843,032.00 |
| Jun 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 1.07 Mn |